Is $^{18}$F-FDG PET/CT useful for diagnosing relapsing polychondritis with airway involvement and monitoring response to steroid-based therapy?

Yunxiang Zeng, Minfang Li†, Sheng Chen, Lin Lin, Shiyue Li, Jianxing He† and Jinlin Wang*†

Abstract

Background: $^{18}$F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is a promising tool for diagnosing relapsing polychondritis (RP). However, its usefulness in assessing RP with airway involvement is unknown.

Objective: This study aimed to further evaluate and confirm the potency of $^{18}$F-FDG PET/CT in diagnosing RP with airway involvement and monitoring response to steroid-based therapy.

Methods: A total of 30 patients from a dedicated respiratory centre, diagnosed with RP in accordance with McAdam, Damiani or Levine criteria, were included in this study. All patients underwent baseline $^{18}$F-FDG PET/CT, and 10 patients underwent second scans after 2.5–15 months of steroid-based therapy. Visual scores (VS) and maximal standard uptake values (SUV max) were analysed.

Results: In the initial scan, 83.3% (25/30) of patients were found to have FDG uptake in more than one cartilage. The median VS and SUV max in the cartilages were 3 (range, 1–3) and 3.8 (range, 1.9–17.9), respectively. Positive rates for PET/CT-guided biopsy in nasal, auricular, and tracheal/bronchial cartilages were 100% (5/5), 88.9% (8/9), and 10.5% (2/19), respectively, but the positive biopsy rate in the auricular cartilage was 92.3% (12/13) even without PET/CT assessment. Based on biopsy-proven sites, the sensitivity of PET/CT was 55.6%, and the specificity was 5.3%. Compared with the baseline scan, the second scan showed much lower median VS (2 vs 3, respectively; $p < 0.0001$) and SUV max (2.9 vs 3.8, respectively; $p < 0.001$). Of 10 patients who underwent second PET/CT, 8 had complete therapeutic response, while 2 had partial response.

Conclusion: $^{18}$F-FDG PET/CT assists in identifying multiple cartilage involvement in RP, but it seems neither a sensitive nor specific modality in diagnosing RP with airway involvement. Moreover, PET/CT has limited utility in locating biopsy sites and monitoring therapeutic response to corticosteroids.

Keywords: $^{18}$F-FDG PET/CT, Relapsing polychondritis, Cartilage, Airway involvement, Corticosteroid, Response to therapy

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Relapsing polychondritis (RP), first described by Jakusch-Wartenhorst in 1923 [1], is a rare autoimmune inflammatory disease characterised by episodic inflammation of the cartilaginous tissue and proteoglycan-rich structures throughout the body [2, 3]. Currently, the diagnosis of RP is still mainly based on clinical manifestations [4–6]. However, the initial symptoms are often atypical, and the diagnosis is unfavourable when the respiratory tract is involved. Airway involvement is a major cause of morbidity and mortality in patients with RP [7] and occurs in up to 50% of patients during the course of the illness [4, 5, 7, 8], but half of these patients had no airway abnormalities on routine inspiratory CT.

In 2007, positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG), as a tracer providing metabolic information on the entire body, was used in a patient with RP [9]. Since then, a few case reports or small case series have demonstrated that PET/CT is capable of determining organ involvement and evaluating disease activity and therapeutic response [10–19]. In 2014, we retrospectively investigated 6 patients with RP and found that PET/CT is a valuable tool in diagnosing RP and monitoring treatment response [20]. Concurrently, Yamashita [21] and Lei [22] analysed a series of patients with RP who underwent PET/CT and concluded that PET/CT is a potentially useful tool for the early diagnosis of RP, especially in patients without easily biopsied organ involvement or with atypical RP. It is also suggested that PET/CT is a radiological tool in the selection of biopsy sites [20–23]. A combination of PET/CT and transbronchial needle aspiration (TBNA) in tracheal/bronchial cartilages was an effective approach of disease diagnosis [22]. However, the value of these investigations was limited by relatively heterogeneous populations and small sample sizes.

In the present study, we retrospectively analysed the data of 30 patients with RP in a respiratory centre. To the best of our knowledge, this is a cohort study with the largest sample size. We aimed to further confirm the value of 18F-FDG PET/CT in disease diagnosis. Moreover, we aimed to investigate the potential usefulness of 18F-FDG PET/CT in response assessment.

Patients and methods
Patients
Patients with RP who visited China Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, due to predominant respiratory symptoms between January 2010 and January 2018 were included in the study. The inclusion criteria were adult patients (≥18 years) diagnosed with to have RP based on either McAdam’s, Damiani and Levine’s or Michet’s criteria [4–6]. A total of 30 patients met the criteria. Patient nos. 1 and 3 were previously reported in separate case reports [13, 23], and information on 6 patients (nos. 1–6) was retrospectively reviewed [20]. The variables and clinical data of these patients were collected for analysis. This study was approved by the Institutional Review Board of the First Affiliated Hospital of Guangzhou Medical University.

18F-FDG PET/CT
As described in our previous study [20], patient preparation for 18F-FDG PET/CT included the following steps: (1) avoidance of strenuous work or exercise in the preceding 24 h, fasting for > 6 h before the scan, and measurement of fasting blood glucose levels before the scan (which were required to be < 130 mg/dL [7.2 mmol/L] before 18F-FDG injection); (2) intravenous injection of 18F-FDG in a dosage of 3.70–5.55 MBq/kg together with 10 mg furosemide to accelerate renal 18F-FDG elimination; (3) CT scan from the brain to the pelvis using a multidetector spiral CT scanner (3.75-mm slice thickness, pitch 0.875, rotation speed 140 keV, 120 mAs) before the PET scan; and (4) acquisition of whole-body PET images using a PET/CT system (GE Discovery ST; GE Medical Systems Inc., WI, USA) 60 min after tracer administration (acquisition time, 2.5 min per bed position for 6 to 7 bed positions). All the PET-scan in our study is full-body PET-scan, and nearly all the cartilaginous zones can be assessed in our patients.

Cartilage biopsy
Auricular cartilage biopsy
Based on the PET/CT findings, auricular cartilages with FDG accumulation were selected. If there is no FDG uptake, the anterior cartilage was used as the biopsy site. After routine disinfection and local anaesthesia, the auricular cartilage with a diameter of approximately 3 mm was obtained and fixed in formalin. Gauze was placed on the biopsy site.

Nasal cartilage biopsy
Biopsies were performed in 5 patients with FDG accumulation in the nasal cartilage by PET/CT. Nasal cartilage biopsies were performed under nasal endoscopy. After routine anaesthesia, the nasal cartilage with a diameter of approximately 3 mm was obtained. If there was no obvious or small amount of bleeding, gauze was placed on the nasal cavity to stop the bleeding. If necessary, bilateral nasal cavities were filled with gauze to stop the bleeding.

Tracheal cartilage biopsy by bronchoscopy
Based on the PET/CT findings, patients underwent conventional bronchoscopy with midazolam, sufentanil and
lipodocaine. The trachea or bronchus with accumulated FDG was biopsied using forceps, and 4–5 tissues were obtained for pathological examination.

**Data analyses**

The PET/CT images were reconstructed using the ordered subset expectation maximisation method, with and without attenuation correction. The visual analysis of PET/CT characteristics and pattern was interpreted by at least 2 experienced nuclear medicine physicians (>20 years of experience in nuclear medicine) who had the patients’ clinical information available on a dedicated workstation. When disputes regarding visual interpretation occurred, consensus was reached by discussion. The $^{18}$F-FDG PET images were analysed visually and semiquantitatively by calculating the maximal standard uptake value ($SUV_{max}$). The intensity of $^{18}$F-FDG uptake by cartilages relative to the background and incompatibility with normal anatomy/physiology was assessed, and the intensity was scored using a 4-point visual scale [24, 25]: 0 = absence, not visible on the image display; 1 = faint or less intense than mediastinal blood pool activity; 2 = moderate or equal in intensity to mediastinal blood pool activity; and 3 = more intense than mediastinal blood pool activity. A region of interest (ROI) was placed over the entire area of any abnormal uptake (scales 2 or 3) site. The $SUV_{\text{max}}$ was calculated (maximum ROI activity/injected dose per kilogram body weight), and the highest $SUV_{\text{max}}$ was used to evaluate the multiple abnormal uptake sites observed in a given lesion or tissue. As the blood glucose level may affect $SUV_{\text{max}}$ results, the $SUV_{\text{max}}$ needed to be corrected for blood glucose level ($SUV_{\text{glu}}$) as follows: $SUV_{\text{glu}} = SUV_{\text{max}} \times \text{blood glucose level}/130$ when the blood glucose level was > 130 mg/dL (7.2 mmol/L) [26]. A positive PET/CT result was indicated by visual score (VS) ≥ 1 or $SUV_{\text{max}}$ ≥ 2.0.

**Statistical analysis**

Continuous variables were presented as median and range, and qualitative variables as numbers and percentages. Intergroup differences were statistically analysed using SPSS® 17.0 (SPSS Inc., Chicago, IL, USA). Differences in continuous variables between groups were compared using Student’s $t$ test. McNemar’s test was used to determine the difference between $^{18}$F-FDG PET/CT and cartilage biopsy in RP diagnosis. Significance in the statistical analyses was set at a $P$ value < 0.05.

**Results**

**Patient baseline characteristics**

A total of 30 patients (17 men, 13 women) with a median age of 44 years (range, 25–66) were included (range, 25–66 years). The main symptom was cough, which was noted in 24 patients (80%); other symptoms included shortness of breath (15/30, 50%), wheezing (6/30, 20%), excessive sputum (6/30, 20%), fever (4/30, 13.3%), hoarseness (3/30, 10%), chest pain (3/30, 10%), and pharyngalgia (1/30, 3.3%). The duration of these symptoms ranged from 6 months to >10 years. The detailed baseline characteristics are shown in Table 1.

**Laboratory test and CT**

Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level varied from normal to markedly increased, with a median level of 45 mm/h (range, 10–121 mm/h) and 17.75 mg/dL (range, 0.03–34.40 mg/dL), respectively. ESR and CRP level were increased in some patients and substantially decreased after regular corticosteroid treatment with a median level of 40 mm/h (range, 11–81 mm/h) and 9.78 mg/dL (range, 0.04–20.30 mg/dL), respectively. Antinuclear antibodies were detectable in 2 patients (case 16 and 19) of 50 U/ml and 48 U/ml, but rheumatoid factor was undetectable. The median fasting blood glucose levels before the initial and follow-up scans were 98.5 mg/dL (range, 78–123 mmol/L) and 103 mg/dL (range, 89–121 mmol/L), respectively ($p = 0.126$). Chest CT before diagnosis showed diffuse thickening and narrowing of the trachea in 26 patients (86.7%), narrowing of the main bronchus in 24 (80%), airway wall calcification in 7 (23.3%), and enlargement of the mediastinal lymph node in 2 (6.7%). One patient (3.3%) had no abnormal manifestations (Table 1). Lung function measurements indicated that 25 patients (75%) had obstructive ventilatory dysfunction and 5 (25%) had restrictive ventilation dysfunction.

**$^{18}$F-FDG PET/CT findings in monitoring disease activity and treatment response**

The initial $^{18}$F-FDG PET/CT scan was performed in all patients. Twenty-five patients (83.3%) had increased uptake in >1 cartilage, and 20 (66.6%) showed increase in ≥3 cartilages. The most commonly involved cartilages were tracheal/bronchial (26/30; 86.7%), nasal (18/30; 60%); and auricular cartilages (15/30; 50%). The median VS in the cartilages was 3. $SUV_{\text{max}}$ was increased in all patients, except 1 patient, and the median value was 3.8 (range, 1.9–17.9). Figure 1 shows the involved cartilages or organs. When these patients were classified into 2 groups according to the history of corticosteroid treatment, 18 patients without history of therapy were found to have FDG accumulation in ≥2 cartilages. However, fewer cartilages were involved than those in patients treated with corticosteroids. Of these 12 patients, 4 (cases 4, 13, 21, and 29) had only 1 cartilage site with intense FDG uptake, and 1 patient (case 7) did not have FDG uptake in any cartilage (Table 2).

Ten patients underwent second PET-CT scans after 2.5–15 months of steroid-based therapy. Most symptoms,
Table 1 Demographic characteristics of the 30 patients with RP

| No. | Age (y) | Chief complaint* (duration; months) | Middiagnosis | Serum levels | ANAs | Lung function | Chest CT scanb | Biopsy site |
|-----|---------|-------------------------------------|--------------|--------------|------|---------------|----------------|-------------|
|     |         |                                     |              | ESR (mm/1 h) | CRP (mg/dL) | RF (IU/mL) | FEV1 (L) | FVC (L) | FEV1/FVC (%) |                     |                     |                     |
|     |         |                                     |              |              |              |            |          |          |             | a                   | b                   |                     |
| 1   | 37/M    | 1 (6)                              | –            | 100          | 22.0         | 2.1        | N         | 1.68     | 4.61         | 36.4                | a, b                | Tracheal (−)/nasal cartilage (+) |
| 2   | 38/M    | 1, 2 (18)                          | Asthma       | 115          | 10.69        | 3.6        | N         | 1.74     | 4.69         | 37.1                | a, b                | Tracheal (−)/auricular (+)    |
| 3   | 55/M    | 1, 3 (6)                           | –            | 10          | 0.03         | 2.4        | N         | 2.57     | 3.32         | 77.3                | c                   | Tracheal (−)/nasal cartilage (+) |
| 4   | 66/F    | 1, 4 (24)                          | COPD         | 105          | 5.36         | 4.2        | N         | 1.64     | 4.56         | 36.0                | e                   | Tracheal (−)/auricular (+)    |
| 5   | 41/M    | 1, 4 (9)                           | –            | 120          | 26.41        | 2.0        | N         | 0.92     | 1.32         | 69.7                | a, b                | Tracheal (−)/auricular (+)    |
| 6   | 55/M    | 1 (10)                             | –            | 112          | 23.41        | 2.8        | N         | 1.32     | 4.19         | 31.46               | a, b                | Tracheal (−)/auricular (+)    |
| 7   | 64/M    | 5 (120)                            | COPD         | 11           | 0.88         | 4.9        | N         | 0.57     | 2.37         | 31.7                | a, b                | Tracheal (−)/auricular (+)    |
| 8   | 60/M    | 4 (72)                             | Amyloidosis  | 23           | 1.02         | 3.4        | N         | 0.49     | 3.37         | 92.3                | a, b, c              | Auricular (+)           |
| 9   | 42/M    | 1, 4, 6 (4)                        | –            | 87           | 16.2         | 2.5        | N         | 1.43     | 4.08         | 35.0                | a, b, c              | Tracheal (−)/auricular (+)    |
| 10  | 47/F    | 1, 4, 7 (1)                        | –            | 45           | 21.0         | 3.1        | N         | 2.30     | 4.02         | 46.5                | b                   | Tracheal (−)/auricular (−)    |
| 11  | 50/F    | 1 (4); 4 (0.5)                     | –            | 34           | 6.4          | 3.0        | N         | 1.10     | 3.67         | 30.0                | b                   | Tracheal (−)/auricular (+)    |
| 12  | 44/F    | 1 (4); 4 (1)                       | Asthma       | 45           | 3.4          | 2.6        | N         | 2.30     | 4.32         | 53.2                | a, b                | Tracheal (−)/auricular (+)    |
| 13  | 44/F    | 1, 5 (10)                          | Asthma       | 68           | 34.4         | 3.2        | N         | 1.70     | 3.89         | 43.7                | a, b                | Tracheal (−)/auricular (+)    |
| 14  | 48/F    | 4 (132)                            | Asthma       | 34           | 10.0         | 1.0        | N         | 0.67     | 2.33         | 28.8                | a, b, c              | Nasal cartilage (+)         |
| 15  | 25/M    | 1, 7 (1); 3 (0.5)                  | –            | 121          | 23.0         | 1.7        | N         | 2.33     | 4.87         | 47.8                | a, b                | Tracheal (−)/auricular (+)    |
| 16  | 26/F    | 1, 4 (6)                           | Asthma       | 56           | 21.0         | 2.6        | 50 U/ml   | 1.02     | 3.24         | 31.5                | a, b                | Auricular (+)           |
| 17  | 52/M    | 1, 5, 7 (60)                       | Asthma       | 45           | 19.3         | 2.5        | N         | 1.05     | 3.45         | 30.4                | b                   | Nasal cartilage (+)         |
| 18  | 43/F    | 4 (6); 1, 5 (2)                     | –            | 34           | 12.0         | 1.3        | N         | 2.00     | 4.01         | 49.9                | a                   | Tracheal (−)/auricular (+)    |
| 19  | 36/F    | 1, 8 (12); 4 (7)                   | –            | 36           | 11.7         | 2.6        | 48 U/ml   | 1.87     | 3.56         | 52.5                | a, b                | Tracheal (−)/auricular (+)    |
| 20  | 36/M    | 6 (12); 4 (6)                      | –            | 110          | 34.12        | 2.1        | N         | 1.56     | 3.67         | 42.5                | a, b, c              | Tracheal (−)/auricular (+)    |
| 21  | 42/M    | 1, 7 (60)                          | Asthma       | 34           | 12.8         | 1.8        | N         | 2.30     | 4.50         | 51.1                | a, b                | Tracheal (−)/auricular (+)    |
| 22  | 45/M    | 1, 3 (7)                           | –            | 22           | 11.33        | 2.3        | N         | 1.20     | 2.05         | 58.5                | a, d                | Auricular (+)           |
| 23  | 34/F    | 2, 4 (8)                           | –            | 56           | 23.0         | 3.5        | N         | 1.98     | 2.87         | 69.0                | a, b, d              | Tracheal (−)             |
| 24  | 62/M    | 1, 7 (36)                          | COPD         | 45           | 21.02        | 2.5        | N         | 1.56     | 3.45         | 45.2                | a, b                | Tracheal (−)/nasal cartilage (+) |
| 25  | 45/F    | 1, 5 (17)                          | –            | 33           | 12.34        | 1.56       | N         | 2.01     | 4.56         | 44.1                | a                   | Tracheal (−)             |
| 26  | 34/F    | 2, 4 (9)                           | –            | 98           | 23.56        | 2.01       | N         | 1.87     | 3.45         | 54.2                | a, b                | Tracheal (−)/auricular (+)    |
| 27  | 29/M    | 1, 3 (8)                           | –            | 121          | 26.71        | 2.76       | N         | 1.23     | 3.56         | 34.6                | a, c                | Auricular (−)            |
| 28  | 45/M    | 1, 5 (14)                          | –            | 56           | 11.0         | 2.04       | N         | 1.34     | 3.21         | 41.7                | a, b, c              | Tracheal (−)/auricular (+)    |
| 29  | 64/M    | 1, 4 (15)                          | Asthma       | 45           | 32.1         | 2.87       | N         | 2.32     | 4.67         | 47.8                | a, b                | Tracheal (−)/auricular (+)    |
| 30  | 35/F    | 1, 6 (12)                          | –            | 36           | 23.1         | 3.45       | N         | 0.97     | 1.89         | 51.3                | a, b                | Tracheal (−)/auricular (+)    |

Chief complaint: 1 = cough, 2 = chest pain, 3 = fever, 4 = shortness of the breath, 5 = wheezing, 6 = hoarseness, 7 = excessive sputum, 8 = pharyngalgia. Chest CT scan: a = diffuse thickening and narrowing of trachea, b = diffuse thickening and narrowing of main bronchus, c = calcification of the trachea, d = enlargement of the mediastinal lymph node, e = no abnormal manifestations.
ANAs antinuclear antibodies, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, ESR erythrocyte sedimentation rate, F female, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, M male, N none, P present, RF rheumatoid factor, RP relapsing polychondritis, y years
such as cough, shortness of breath, excessive sputum, and fever, were relieved. After systemic corticosteroid therapy, 8 patients had complete therapeutic response, while 2 patients had partial response. One patient had relapse and died in the 3-year follow-up due to tracheal stenosis. Most importantly, VS (2 vs 3, \( p < 0.0001 \)) and SUV\(_{\text{max}}\) (2.9 vs 3.8, \( p < 0.001 \)) significantly decreased. FDG uptake decreased or disappeared during corticosteroid therapy in a majority of patients. FDG uptake diminished in most involved cartilages, except in the auricular cartilage of case 24 but with complete therapeutic response (Fig. 2).

### Cartilage biopsy findings

The results of cartilage biopsies performed at different sites in all patients are shown in Table 3. \(^{18}\)F-FDG PET/CT showed 5 true positives for nasal cartilage in 5 patients. Bronchoscopy with the aid of PET/CT was performed in 19 patients. However, based on biopsy-proven sites (tracheal/bronchial cartilage), the sensitivity of PET/CT was 10.53% (2/19). Four patients who underwent biopsies of the tracheal/bronchial cartilage by bronchoscopy all had negative findings (0/4, 0%). Eight (88.9%) of 9 biopsy-proven sites (auricular cartilage) were detected using \(^{18}\)F-FDG PET/CT. Figure 3 presents the histology of a patient. Even without the assistance of PET/CT, the positive rate of auricular cartilage biopsy was up to 92.31% (12/13). Therefore, no correlation was found between PET/CT and biopsy in RP diagnosis with respect to the auricular cartilage.

### Discussion

RP is a rare inflammatory chondropathy in multiple cartilages that is not readily diagnosed in the absence of typical clinical findings [2, 20, 27–31]. The diagnosis of RP is still based on clinical grounds [4, 5], and histologic confirmation is not required. According to Damiani and Levine [6], the diagnosis can be established when one or more clinical features are present in conjunction with biopsy confirmation. Our previous study revealed that PET/CT is a powerful tool in diagnosing RP as it can detect multisystemic cartilaginous abnormalities via increased FDG uptake [20]. Yamashita et al. [21] found several specific patterns of PET/CT findings in RP, such as FDG uptake in bilateral auricular cartilage, and FDG uptake was noted in various combinations of affected lesions in a single patient. These authors believe that the specific PET/CT findings may be of high diagnostic value. However, the number of patients in these studies was small. To our best knowledge, the current study has the largest patient population. Significantly, PET/CT showed that 83.3% (25/30) of patients had involvement in > 1 cartilage. We also found that all 18 patients without history of corticosteroid treatment had involvement in > 1 cartilage. Therefore, FDG uptake in multiple cartilages, such as tracheal/bronchial, nasal and auricular cartilages, in a single patient suggests the diagnosis of RP, and a biopsy might not be necessary. However, the other 12 patients who received irregular corticosteroid treatment previously had fewer involved
cartilages detected by PET/CT, and 4 of them had only one site of intense FDG uptake in cartilages. One patient who had received corticosteroid treatment did not exhibit intense FDG uptake in any cartilages. Thus, repeated administration of corticosteroids may undermine the diagnostic value of 18F-FDG PET/CT.

Although biopsy of inflamed sites is not routinely performed, the detection of basophilic staining of the cartilage matrix, perichondral round-cell infiltration, or cartilage destruction with fibrous replacement can have diagnostic value [32]. Based on the criteria by Damiani and Levine, who expanded the spectrum diagnostic criteria, positive histologic confirmation is helpful in RP diagnosis. In our respiratory centre, definitive diagnosis of RP is usually made according to both clinical manifestation and biopsy findings, especially in patients with atypical clinical presentation or in early stages. The main biopsy sites are the auricular and nasal cartilages, which are relatively easy and safe to obtain. We found that the positive rate of PET/CT-guided biopsy was 100% in the nasal cartilage (5/5) and 88.9% in auricular cartilage (8/9), and this rate was 92.3% in the auricular cartilage even

### Table 2 FDG-PET/CT findings of RP in the 30 patients

| No. | Initial PET/CT scan | Follow-up PET/CT scana | SUVmaxc | Initial PET/CT scan | Follow-up PET/CT scana | SUVmaxc | Interval (months) |
|-----|---------------------|------------------------|---------|---------------------|------------------------|---------|-----------------|
| 1   | 101                 | 1/2/3/4               | 3/3/3/3 | 5.8/5.7/3.6/5.1     | 116                    | 3/3/1/3 | 3.1/2.7/2.7     | 3       |
| 2   | 89                  | 1/2/3/4/5/6/7         | 3/3/3/3/3 | 3.8/3.7/4.0/3.9/4.0/3.8/3.7 | 101     | 2/2/0/3/0/0     | 2.0/2.1/2.1/3.1/3.1/3.1 | 3       |
| 3   | 83                  | 2/3/4/6/7/8           | 3/3/3/3/3 | 4.4/4.2/3.8/3.8/3.8/4.8 | 98      | 3/0/3/3/3      | 3.8/3.0/3.0/3.0/3.0   | 2.5     |
| 4   | 93                  | 6                     | 3        | 3.6                 |                       |         |                 |         |
| 5   | 93                  | 1/3/8/9               | 3/3/3/3 | 3.3/4.2/4.5/5.0     | 89       | 2/0/3/3        | 2.1/3.0/2.8     | 3       |
| 6   | 115                 | 1/8                   | 3/3      | 3.5/4.2             | 108       | 3/0           | 2.8/2.8/2.8    | 4       |
| 7   | 85                  | –                     | –        | –                   |                       |         |                 |         |
| 8   | 116                 | 1/9                   | 3/3      | 3.0/2.5             |                       |         |                 |         |
| 9   | 88                  | 1/9/10                | 3/3/3    | 3.3/4.5/4.3         |                       |         |                 |         |
| 10  | 79                  | 1/10                  | 3/3      | 3.1/4.3             |                       |         |                 |         |
| 11  | 112                 | 1/8                   | 3/3      | 3.3/3.8             |                       |         |                 |         |
| 12  | 101                 | 1/3/8/11              | 3/3/3/3 | 5.9/2.8/3.2/5.7     | 121       | 3/0/0/0        | 2.8/2.8/2.8    | 3       |
| 13  | 122                 | 10                    | 3        | 4.0                 |                       |         |                 |         |
| 14  | 99                  | 1/2                   | 3/3      | 3.4/3.8             |                       |         |                 |         |
| 15  | 87                  | 1/2/8/10              | 3/3/3/3 | 3.8/4.9/4.9/3.5     |                       |         |                 |         |
| 16  | 110                 | 1/2/3/9/10            | 3/3/3/3 | 2.5/2.6/2.2/4.7/2.6 |                       |         |                 |         |
| 17  | 95                  | 1/2/8/12              | 1/3/3   | –/6.2/3.2/2.7       | 113       | 0/2/0/0        | –/3.0/-/2.0/2.0 | 4       |
| 18  | 123                 | 1/2/8/10              | 1/2/3   | –/1.9/3.0/2.2       |                       |         |                 |         |
| 19  | 101                 | 1/2/8/10              | 3/3/3/3 | 2.7/3.7/3.0/5.5     |                       |         |                 |         |
| 20  | 111                 | 1/2/4/8/10            | 3/3/3/3 | 3.2/3.2/4.2/4.0/4.2 | 110       | 0/3/0/2/0      | –/3.9/-/2.0/2.0  | 3       |
| 21  | 121                 | 1                     | 3        | 2.0                 |                       |         |                 |         |
| 22  | 96                  | 1/2/9                 | 3/1/3   | 3.8/–/6.4           |                       |         |                 |         |
| 23  | 98                  | 1/2/3/8/9/10          | 3/3/3/3 | 3.7/3.0/4.5/3.5/3.5/3.2 |                       |         |                 |         |
| 24  | 99                  | 1/2/3/8/10            | 3/3/3/3 | 3.8/2.7/8.1/3.6/7.2 | 103       | 0/0/0/3/0      | –/–/–/4.2/–     | 4       |
| 25  | 78                  | 1/2/3/8               | 3/3/3/3 | 2.2/3.3/4.0/4.3     |                       |         |                 |         |
| 26  | 108                 | 1/2/3/8/10            | 3/2/3/2 | 4.8/1.8/2.8/1.7/3.8 |                       |         |                 |         |
| 27  | 97                  | 1/2/8/10              | 3/3/3    | 4.0/2.9/3.9/4.9     | 102       | 0/0/1/3        | –/–/1.2/2.8    | 3       |
| 28  | 87                  | 1/2/13                | 3/3/3   | 9.1/4.9/17.9        |                       |         |                 |         |
| 29  | 98                  | 1                     | 2        | 2.0                 |                       |         |                 |         |
| 30  | 102                 | 1/2/3/9/10            | 3/3/3/3 | 4.6/3.2/4.5/4.7/5.0 |                       |         |                 |         |

**FDG-PET/CT** fluorescent glucose positron emission tomography/computed tomography, **FBG** fasting blood glucose, **SUVmax** maximum standardised uptake value

*a*Results of the second PET/CT scan, even though 3 follow-up scans could be performed

*b*Uptake sites: 1 = tracheal/bronchial cartilage; 2 = nasal cartilage; 3 = costicartilage; 4 = arytenoid cartilage; 5 = hyoid cartilage; 6 = cricoid cartilage; 7 = thyroid cartilage; 8 = auricular cartilage; 9 = lymph node; 10 = auricular cartilage; 11 = vocal cord; 12 = lung; 13 = eye muscle

*c*If the FDG uptakes were in different positions of the same cartilage, SUVmax should be representative of the highest one
without PET/CT (12/13). This finding reveals that PET/CT is not sensitive and specific in the identification of patients with RP with auricular involvement. A possible explanation is that FDG accumulates less in the auricular cartilage due to poor blood supply.

In terms of examining tracheal involvement, PET/CT is sufficient to provide accurate visualisation of RP by demonstrating increased FDG uptake in tracheal cartilages, airway wall thickening, airway stenosis, airway malacia, airway wall calcification, and air trapping. In our study, the positive rate of PET/CT-guided biopsy was low in the tracheal/bronchial cartilage (10.5%), even though FDG uptake was high. Therefore, a positive PET/CT finding is inconsistent with biopsy finding in the tracheal/bronchial walls by bronchoscopy. The reason for such difference may lie in the technical difficulty in accessing tracheal/bronchial cartilages when there is tracheal collapse, fibrosis, or stenosis. Bronchoscopy is invasive and may consequently exacerbate mucosal swelling or cartilage inflammation via mechanical stimulation [7]. Serious complications arising from cartilage biopsies of the trachea or bronchus in patients with RP have been reported [33]. Therefore, the value of PET/CT-guided biopsy seems limited in inaccessible sites that are of clinical significance.

Corticosteroid therapy is the mainstay of treatment for RP, and some researchers have reported that PET/CT is valuable for monitoring the treatment response. Lei et al. [22] noted that post-treatment PET/CT showed obvious decreases or complete disappearance of high

**Fig. 2** A 44-year-old woman with RP showed multicartilage involvement. **a** A whole-body view showed multiple foci of pathological tracer uptake in cartilages (vocal cord, SUV_{max} 5.8; tracheal/bronchial cartilage, SUV_{max} 5.8; red arrowhead). **b** The SUV_{max} of the tracheal cartilage was approximately 5.8 (red arrowhead). **c** Abnormal uptake was detected in the costicartilage and tracheal cartilage (red arrowhead).
18F-FDG uptake lesions in 10 of 22 cases, which were highly consistent with symptom improvement, and Yamashita et al. [21] reported similar findings. In our study, a follow-up scan performed in 10 (33%) of 30 patients showed that median VS and SUV_max were significantly decreased after therapy. These changes were also correlated with clinical symptom improvement and laboratory tests.

These findings suggest that PET/CT is a promising radiological tool in monitoring treatment response and disease progression. However, because there is no agreement regarding the duration of corticosteroid treatment, there is no consensus regarding the use of PET/CT to optimise corticosteroid strategies, although some studies have revealed its potential value [10–16]. The interval for PET/CT scans after corticosteroid therapy remains unclear, as it has been reported to range from 1 month to 13 months [10–12, 14, 21]. To our best knowledge, there is no evidence that PET/CT can provide prognostic information in patients with RP and could be considered a guide for making treatment decisions. In 2 of our patients, in whom follow-up data indicated symptomatic and inflammatory improvement, FDG uptake diminished in most affected sites but increased in 2 other sites (nasal and auricular cartilages). Thus, in some patients, PET/CT results may differ depending on their symptoms. In some cartilage sites, FDG accumulation after corticosteroid treatment of patients with RP may be correlated with other factors (except inflammatory activity).

In the present study, only 33.3% of patients (10/30) underwent follow-up PET/CT, mainly because of radiation exposure and high cost in developing countries, and further studies involving larger numbers of patients are necessary to evaluate the role of follow-up PET/CT scans during treatment. Thus, the cost-effectiveness of repeated PET/CT scans and the resultant radiation exposure must also be considered.

Our study has some limitations. First, it is a retrospective study; therefore, the results may not completely translate to clinical practice. Second, because all patients included in the study presented with respiratory symptoms, it is possible that we underestimated the value of PET/CT in patients with RP without respiratory involvement. Lastly, the number of patients was still extremely small to reflect the low incidence of this disease and well-defined patient populations. Thus, a larger, multicentre,

**Table 3** Correlation of PET/CT with cartilage biopsy in diagnosing RP

| PET/CT¹ | Cartilage biopsy | Total |
|---------|-----------------|-------|
|         | Positive | Negative |       |
| Nasal cartilage | 5       | 0       | 5     |
| Positive | 0       | 0       | 0     |
| Total | 5       | 0       | 5     |

McNemar’s chi-square test: $\chi^2 = NaN; p = NaN$

| Auricular cartilage | Positive | Negative | Total |
|---------------------|----------|----------|-------|
| Positive | 8       | 1        | 9     |
| Negative | 12      | 1        | 13    |
| Total | 20      | 2        | 22    |

McNemar’s chi-square test: $\chi^2 = 7.69; p = 0.005$

| Tracheal/bronchial cartilage | Positive | Negative | Total |
|-------------------------------|----------|----------|-------|
| Positive | 2       | 17       | 19    |
| Negative | 0       | 4        | 4     |
| Total | 2       | 21       | 23    |

McNemar’s chi-square test: $\chi^2 = 15.1; p = 0.001$

¹PET/CT positron emission tomography/computed tomography, NaN not a number, RP relapsing polychondritis

PET/CT-guided biopsy was performed in affected cartilage when PET/CT showed increased FDG uptake
prospective, randomised study is needed for further validation of our results.

Conclusions

18F–FDG PET/CT helps identify multiple cartilage involvement in RP but seems neither sensitive nor specific in evaluating RP with airway involvement. Moreover, PET/CT has limited utility in locating biopsy sites and monitoring response to corticosteroid treatment.

Abbreviations

18F–FDG PET/CT: 18F-fluorodeoxyglucose positron emission tomography/computed tomography; ANA: Antinuclear antibody; COPD: Chronic obstructive pulmonary disease; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; HRCT: High-resolution computed tomography; OSEM: Ordered subset expectation maximisation method; RF: Rheumatoid factor; ROI: Region of interest; RP: Relapsing polychondritis; SUVmax: Maximal standard uptake value; TBNA: Transbronchial needle aspiration; VS: Visual score

Acknowledgements

Editorial assistance with the manuscript was provided by Shanghai Youjin Biotechnology Co., Ltd.

Authors’ contributions

JW and JH contributed to the conception, design of the study, data analysis, interpretation and revision of the manuscript. YZ and ML contributed to data analysis and manuscript writing. SC, LL and SL contributed to data interpretation and revision of manuscript. All authors reviewed and approved the manuscript prior to submission for publication.

Funding

None.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the Institute Review Board of the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. All patients provided informed consent to participate in the study.

Consent for publication

All patients provided informed consent to publish the data.

Competing interests

The authors declare that they have no competing interests.

Author details

1The State Key Laboratory of Respiratory Disease, China Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou 510120, Guangdong Province, China. 2The Second School of Clinical Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China. 3Department of Respiratory Medicine, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China. 4Department of Respiratory Medicine, Guangdong Hospital of Traditional Chinese Medicine, Second Clinical Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.

Received: 6 October 2019 Accepted: 4 December 2019

Published online: 12 December 2019

References

1. Jakob-Wantenhorst R. Polychondropathia. Wien Arch Inn Med. 1923;69:3–100.
2. Lahmert T, Treiber M, von WA FF, Knopf A, Heemann U, et al. Relapsing polychondritis: an autoimmune disease with many faces. Autoimmun Rev. 2010;9:540–6.
3. Pearson CM, Kline HM, Newcomer VD. Relapsing polychondritis. N Engl J Med. 1960;263:51–8.
4. McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976;55:193–215.
5. Michet CJ, McIlhenny CH, Luthra HS, OFallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med. 1986;104:74–8.
6. Darniani JM, Levine HL. Relapsing polychondritis–report of ten cases. Laryngoscope. 1979;89:929–46.
7. Ernst A, Rafae S, Boiselle P, Sung A, Reddy C, Michaud G, et al. Relapsing polychondritis and airway involvement. Chest. 2009;135:1024–30.
8. Chang SJ, Lu CC, Chung YM, Lee SS, Chou CT, Huang DF. Laryngotracheal involvement as the initial manifestation of relapsing polychondritis. J Chin Med Assoc. 2005;68:279–82.
9. Nishiyama Y, Yamamoto Y, Dobashi H, Kameda T, Satoh K, Ohkawa M. [18F]fluorodeoxyglucose positron emission tomography imaging in a case of relapsing polychondritis. J Comput Assist Tomogr. 2007;31:381–3.
10. De Geeter T, Vandecasteele SJ. Fluorodeoxyglucose PET in relapsing polychondritis. N Engl J Med. 2008;358:36–7.
11. Yokoyama T, Koyama N, Koda K, Hagiwara K, Kanazawa M. F-fluorodeoxyglucose positron emission tomography for relapsing polychondritis as a diagnostic approach and evaluation of disease activity. BMJ Case Rep. 2009;2009:bcr02.2009.1591.
12. Sato M, Hiyama T, Abe T, Ito Y, Yamaguchi S, Uchiimi K, et al. F-18 FDG PET/CT in relapsing polychondritis. Ann Nucl Med. 2010;24:680–90.
13. Deng H, Chen P, Wang L, Li X, Yi J. Relapsing polychondritis on PET/CT. Clin Nucl Med. 2012;37:712–5.
14. Cassone G, Lo GA, Bajocchi G, Salvatorini C. [18F]fluorodeoxyglucose positron emission tomography imaging in a case of relapsing polychondritis. Rheumatology (Oxford). 2012;51:1813.
15. Horne K, Nagashima T, Onishi S, Nagatani K, Iwamoto M, Minota S. Fluorodeoxyglucose positron emission tomography/computed tomography for diagnostic imaging in relapsing polychondritis with atypical manifestations. J Clin Rheumatol. 2013;19:104–5.
16. Czepczyński R, Guzikowska-Rutkowska I, Wyszomirsk A. Relapsing polychondritis detected in PET/CT. Eur J Nucl Med Mol Imaging. 2012;39:1366–7.
17. Ikeda S, Arita M, Ikeo S, Nishiyama A, Ito A, Furuta K, et al. Chronic treatment of airway lesions in relapsing polychondritis by positron emission tomography. Intern Med. 2015;54:1099–102.
18. Baudart P, Aoubab A, Beauffrère M, Aide N. 18F-FDG PET-CT and 18F-FDG PET/CT as a powerful tool for diagnosing and monitoring treatment outcomes of relapsing polychondritis. Eur J Nucl Med Mol Imaging. 2018;45:669–70.
19. Yamashita H, Kubota K, Minomo A. Clinical value of whole-body PET/CT in patients with active rheumatic diseases. Arthritis Res Ther. 2014;16:423.
20. Wang J, Li S, Zeng Y, Chen P, Zhang N, Zhong N. 18F–FDG PET/CT is a valuable tool for relapsing polychondritis diagnose and therapeutic response monitoring. Ann Nucl Med. 2014;28:276–84.
21. Yamashita H, Takahashi H, Kubota K, Ueda Y, Ozaki T, Yoriuchi H, et al. Utility of fluorodeoxyglucose positron emission tomography/computed tomography for early diagnosis and evaluation of disease activity of relapsing polychondritis: a case series and literature review. Rheumatology (Oxford). 2014;53:1482–90.
22. Lei W, Zeng DX, Chen T, Jiang JH, Wang CG, Zhu YH, et al. FDG PET-CT combined with TBNA for the diagnosis of atypical relapsing polychondritis: report of 2 cases and a literature review. J Thorac Surg. 2014;61:285–92.
23. Li M, Zeng Y, Xie X, Wang J, Chen S. A case of relapsing polychondritis solely presenting with chronic cough. Int J Clin Exp Med. 2017;10:16745–9.
24. Reidt JB, Colen RR, King K, Fischman AJ, Mueller PR, Blake MA. Visual PET/CT scoring for nonspecific 18F-FDG uptake in the differentiation of early malignant and benign esophageal lesions. AJR Am J Roentgenol. 2008;191:515–21.
25. Nomori H, Watanabe K, Ohtsu T, Naruke T, Suemasu K, Uno K. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann Thorac Surg. 2005;79:6084–8 discussion 989.
26. Koyama K, Okamura T, Laryngoscope. 1979;89:929–46.
27. Vitale A, Sota J, Rigante D, Lopalo G, Molinaro F, Messina M, et al. Relapsing polychondritis: an update on pathogenesis, clinical features, diagnostic tools, and therapeutic perspectives. Curr Rheumatol Rep. 2016;18:3.
28. Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, Takeuchi T. Polychondritis presenting with oculomotor and abducens nerve palsies as the initial manifestation. Mod Rheumatol. 2016;26:790–3.

29. Defer GL, Danaila T, Constans JM, Derache N. Relapsing polychondritis revealed by basal ganglia lesions. Mov Disord. 2012;27:1094–6.

30. Jain VK, Ashdeep GS. Erythema multiforme: a rare skin manifestation of relapsing polychondritis. Int J Dermatol. 2014;53:1272–4.

31. Watanabe M, Suzuki H, Ara T, Nishizuka M, Morita M, Sato C, et al. Relapsing polychondritis complicated by giant cell myocarditis and myositis. Intern Med. 2013;52:1397–402.

32. Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med. 1998;129:114–22.

33. O’Connor RC, Garcia IWT, Baron RFJ, Garcia ME, Luque BR, Gomez AD. When is a biopsy justified in a case of relapsing polychondritis? J Laryngol Otol. 1999;113:663–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.